Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Rhea-AI Summary

Alnylam Pharmaceuticals, Inc. will present company overviews at three upcoming healthcare conferences in November 2023, providing live audio webcasts and replays on their website.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

• Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 10:00 am GMT (5:00 am ET) in London
• Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 9:45 am ET at the Lotte New York Palace Hotel in New York City
• Piper Sandler 35^th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am ET at the Lotte New York Palace Hotel in New York City

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), AMVUTTRA^® (vutrisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), and Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231107524076/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

What conferences will Alnylam Pharmaceuticals, Inc. present at in November 2023?

Alnylam Pharmaceuticals, Inc. will present at the Jefferies London Healthcare Conference, Stifel 2023 Healthcare Conference, and Piper Sandler 35th Annual Healthcare Conference in November 2023.

Where can I access the live audio webcast of the presentations?

The live audio webcast will be available on the Investors section of Alnylam Pharmaceuticals, Inc.'s website at www.alnylam.com/events.

When will the replays of the presentations be available?

Replays will be available on Alnylam Pharmaceuticals, Inc.'s website within 48 hours after each event.